Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.70
+0.02 (0.21%)
At close: Dec 12, 2025, 4:00 PM EST
9.62
-0.08 (-0.82%)
After-hours: Dec 12, 2025, 7:56 PM EST
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
179.73M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRBP News
- 1 day ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 1 day ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire
- 2 days ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha
- 6 weeks ago - Corbus Pharmaceuticals Announces Pricing of Public Offering - GlobeNewsWire
- 6 weeks ago - Corbus Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript - Seeking Alpha